CareDx, Inc (CDNA)
NASDAQ: CDNA · Real-Time Price · USD
17.84
+0.06 (0.34%)
At close: Apr 23, 2025, 4:00 PM
17.81
-0.03 (-0.17%)
Pre-market: Apr 24, 2025, 4:31 AM EDT
CareDx Revenue
In the year 2024, CareDx had annual revenue of $333.79M with 19.07% growth. CareDx had revenue of $86.58M in the quarter ending December 31, 2024, with 32.04% growth.
Revenue (ttm)
$333.79M
Revenue Growth
+19.07%
P/S Ratio
2.82
Revenue / Employee
$513,515
Employees
650
Market Cap
988.80M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 333.79M | 53.46M | 19.07% |
| Dec 31, 2023 | 280.32M | -41.47M | -12.89% |
| Dec 31, 2022 | 321.79M | 25.40M | 8.57% |
| Dec 31, 2021 | 296.40M | 104.20M | 54.22% |
| Dec 31, 2020 | 192.19M | 65.13M | 51.25% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.90B |
CDNA News
- 2 days ago - CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 15 days ago - CareDx to Report First Quarter 2025 Financial Results - Business Wire
- 26 days ago - CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA - Business Wire
- 4 weeks ago - CI Global Asset Management Announces Securityholder Approval of Fund Mergers - Business Wire
- 5 weeks ago - CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA - PRNewsWire
- 6 weeks ago - CareDx Launches Two Expanded Indications for AlloSure Testing Services - Business Wire
- 2 months ago - CareDx, Inc (CDNA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - CareDx Announces Fourth Quarter and Full Year 2024 Financial Results - Business Wire